Brief: Updates From Decide Study Involving Decisiondx-Melanoma Test

Castle Biosciences

20/10/2022 23:23

Oct 20 (Reuters) - Castle Biosciences Inc  CSTL.O :
    * NEW DATA FROM DECIDE STUDY SHOW THE SIGNIFICANT ROLE OF
DECISIONDX®-MELANOMA TEST RESULTS AND PATIENT PREFERENCE IN
DECISIONS TO PERFORM THE SENTINEL LYMPH NODE BIOPSY (SLNB)
SURGICAL PROCEDURE

Source text for Eikon:  ID:nBwtDFqsa 
Further company coverage:  CSTL.O 
 ((reuters.briefs@thomsonreuters.com;))